Abstract
Background The relative risk of smoking on lung cancer have been reported to be much higher in white population than that in East Asians. However, it’s unknown whether genetic background underlies this disparity between ethnic groups. To assess the role of ethnic differences in genetic factors associated with this phenomenon.
Methods We first constructed ethnic-specific polygenic risk scores (PRSs) to quantify individual genetic risk of lung cancer in Chinese and white populations. Then, we compared genetic risk and smoking as well as their interactions on lung cancer between two cohorts, including the China Kadoorie Biobank (CKB) and the UK Biobank (UKB). We also evaluated the absolute risk reduction over a 5-year period.
Results 19 SNPs and 23 SNPs were identified to construct the PRSs in Chinese and white populations, and smoking-related loci were only included in white populations. The PRSs were consistently associated with lung cancer risk respectively, but stronger associations were observed in smokers of the UKB (HR 1.26 versus 1.15, P=0.028). A significant interaction between genetic risk and smoking on lung cancer was observed in the UKB (RERI, 11.39 [95% CI, 7.01-17.94]), but not in the CKB. By comparing heavy smokers with nonsmokers, a greater absolute risk reduction was found in the UKB (10.95 versus 7.12 per 1000 person-years, P<0.001), especially for those at high genetic risk.
Conclusions In China, tobacco control alone is not enough to reduce the burden of lung cancer, and comprehensive policies should be made to lower its high incidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China (81820108028, 91943301, 81922061, 81973123, and 81803306); Research Unit of Prospective Cohort of Cardiovascular Diseases and Cancers, Chinese Academy of Medical Sciences (2019RU038); National Science Foundation for Post-doctoral Scientists of China (Grant No.2018M640466).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Researchers can apply to use the UK Biobank and the China Kadoorie Biobank resource and access the data used. No additional data are available.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Researchers can apply to use the UK Biobank and the China Kadoorie Biobank resource and access the data used. No additional data are available.
Abbreviations
- AP
- the attributable proportion because of the interaction
- CI
- confidence interval
- CKB
- the China Kadoorie Biobank
- GWAS
- genome-wide association study
- HR
- hazards ratio
- ICD-10
- the 10th Revision of International Classification of Diseases
- OR
- odds ratio
- PRS
- polygenic risk score
- RERI
- relative excess risk due to interaction
- RR
- relative risk
- SNP
- single-nucleotide polymorphism
- UKB
- the UK Biobank
